Table 3.
The frequencies of the nucleotide substitutions in the EnhII/BCP/PC region of HBV in the HCC patients and HCC survival
| Substitutions | HCC Patients | Deaths | MST | Log‐rank | Crude HR | P value | Adjusted HRa | P valuea |
|---|---|---|---|---|---|---|---|---|
| N (%) | N (%) | (mo) | P value | (95% CI) | (95% CI)a | |||
| C1653T | ||||||||
| C | 201 (74.2) | 160 (79.6) | 14.69 | — | 1 | — | 1 | — |
| T | 70 (25.8) | 52 (74.3) | 10.71 | 0.868 | 1.03 (0.75‐1.41) | 0.868 | 0.93 (0.67‐1.27) | 0.635 |
| C1673T | ||||||||
| C | 229 (84.5) | 178 (77.7) | 13.54 | — | 1 | — | 1 | — |
| T | 42 (15.5) | 34 (81.0) | 13.54 | 0.495 | 1.14 (0.79‐1.64) | 0.496 | 1.22 (0.84‐1.78) | 0.293 |
| T1674C/G | ||||||||
| T | 193 (71.2) | 151 (55.7) | 13.34 | — | 1 | — | 1 | — |
| C/G | 78 (28.8) | 61 (22.5) | 16.00 | 0.659 | 0.94 (0.69‐1.26) | 0.660 | 0.84 (0.62‐1.14) | 0.255 |
| A1703G | ||||||||
| A | 231 (85.2) | 178 (65.7) | 13.54 | — | 1 | — | 1 | — |
| G | 40 (14.8) | 34 (12.6) | 14.29 | 0.753 | 1.06 (0.73‐1.53) | 0.753 | 1.05 (0.72‐1.52) | 0.814 |
| G1719T | ||||||||
| G | 88 (32.5) | 70 (25.8) | 14.49 | — | 1 | — | 1 | — |
| T | 183 (67.5) | 142 (52.4) | 12.85 | 0.603 | 0.93 (0.70‐1.24) | 0.604 | 0.87 (0.65‐1.17) | 0.353 |
| A1726C | ||||||||
| A | 233 (86.0) | 184 (67.9) | 13.54 | — | 1 | — | 1 | — |
| C | 38 (14.0) | 28 (10.3) | 13.54 | 0.860 | 1.04 (0.70‐1.54) | 0.860 | 0.99 (0.66‐1.48) | 0.954 |
| T1727A/G | ||||||||
| T | 42 (15.5) | 32 (76.2) | 13.54 | — | 1 | — | 1 | — |
| A/G | 229 (84.5) | 180 (78.6) | 13.54 | 0.556 | 0.89 (0.61‐1.30) | 0.557 | 0.94 (0.64‐1.38) | 0.752 |
| C1730G | ||||||||
| C | 229 (84.5) | 181 (79.0) | 13.44 | — | 1 | — | 1 | — |
| G | 42 (15.5) | 31 (73.8) | 14.49 | 0.778 | 1.06 (0.72‐1.55) | 0.778 | 1.02 (0.69‐1.51) | 0.904 |
| A1752G | ||||||||
| A | 242 (89.3) | 191 (78.9) | 13.44 | — | 1 | — | 1 | — |
| G | 29 (10.7) | 21 (72.4) | 15.47 | 0.872 | 0.96 (0.61‐1.51) | 0.872 | 1.06 (0.67‐1.67) | 0.809 |
| T1753C | ||||||||
| T | 176 (64.9) | 142 (80.7) | 12.58 | — | 1 | — | 1 | — |
| C | 95 (35.1) | 70 (73.7) | 16.30 | 0.034 | 0.73 (0.55‐0.97) | 0.035 | 0.75 (0.56‐1.01) | 0.059 |
| A1762T | ||||||||
| A | 51 (18.8) | 39 (76.5) | 14.49 | — | 1 | — | 1 | — |
| T | 220 (81.2) | 173 (78.6) | 13.54 | 0.765 | 1.05 (0.74‐1.49) | 0.766 | 1.05 (0.74‐1.49) | 0.789 |
| G1764A | ||||||||
| G | 33 (12.2) | 23 (69.7) | 14.46 | — | 1 | — | 1 | — |
| A | 238 (87.8) | 189 (79.4) | 13.54 | 0.700 | 1.09 (0.71‐1.68) | 0.701 | 1.07 (0.69‐1.66) | 0.757 |
| A1762T/G1764A | ||||||||
| A/G | 32 (9.7) | 22 (73.9) | 14.46 | — | 1 | — | 1 | — |
| T/A | 299 (72.2) | 236 (79.5) | 14.29 | 0.699 | 1.09 (0.70‐1.69) | 0.699 | 1.08 (0.70‐1.68) | 0.723 |
| G1799C | ||||||||
| G | 48 (17.7) | 36 (75.0) | 14.69 | — | 1 | — | 1 | — |
| C | 223 (82.3) | 176 (78.9) | 12.85 | 0.983 | 1.00 (0.70‐1.44) | 0.983 | 1.15 (0.80‐1.66) | 0.457 |
| A1846T | ||||||||
| A | 172 (63.5) | 139 (80.8) | 13.34 | — | 1 | — | 1 | — |
| T | 99 (36.5) | 73 (73.7) | 14.46 | 0.585 | 0.92 (0.70‐1.23) | 0.585 | 0.95 (0.71‐1.27) | 0.728 |
| G1896A | ||||||||
| G | 119 (43.9) | 94 (79.0) | 15.47 | — | 1 | — | 1 | — |
| A | 152 (56.1) | 118 (77.6) | 13.01 | 0.245 | 1.17 (0.89‐1.54) | 0.246 | 1.23 (0.94‐1.63) | 0.137 |
| G1899A | ||||||||
| G | 187 (69.00) | 152 (81.28) | 12.85 | — | 1 | — | 1 | — |
| A | 84 (31.00) | 60 (71.43) | 16.10 | 0.067 | 0.76 (0.56‐1.02) | 0.068 | 0.69 (0.51‐0.95) | 0.020 |
| G1915A/C | ||||||||
| G | 229 (84.5) | 177 (77.3) | 14.65 | — | 1 | 1 | ||
| A/C | 42 (15.5) | 35 (83.3) | 11.56 | 0.653 | 1.09 (0.76‐1.56) | 0.654 | 1.44 (0.98‐2.10) | 0.061 |
| C1969T | ||||||||
| C | 234 (86.4) | 181 (77.4) | 13.70 | — | 1 | 1 | ||
| T | 37 (13.7) | 31 (83.8) | 12.42 | 0.766 | 1.06 (0.72‐1.55) | 0.766 | 1.11 (0.76‐1.64) | 0.581 |
| A1979G | ||||||||
| A | 230 (84.9) | 181 (78.7) | 13.54 | — | 1 | 1 | ||
| G | 41 (15.1) | 31 (75.6) | 14.95 | 0.396 | 0.85 (0.58‐1.24) | 0.397 | 0.83 (0.56‐1.22) | 0.341 |
a
Cox proportional hazard regression analyses adjusted for age, gender, smoke, drink, BCLC stage, and chemotherapy or TACE.